Inhibrx Biosciences' Shares Up Ahead of Phase 2 Head and Neck Cancer Drug Data

Dow Jones

May 09

By Elias Schisgall

Shares of Inhibrx Biosciences rose after the clinical-stage biopharmaceutical company said it would release data from a Phase 2 study of INBRX-106, a potential cancer treatment.

Shares were up 6.4% to $142.90 after the bell on Friday. The stock closed up 7.9% at $134.35, and has risen more than 1,000% in the past 52 weeks.

The company will read out the data in a webcast at 8:30 a.m. ET on Monday.

INBRX-106, a hexavalent OX40 agonist, is being tested in combination with pembrolizumab to treat metastatic or unresectable recurrent Head and Neck Squamous Cell Carcinoma. It is being tested against pembrolizumab as a monotherapy.

Write to Elias Schisgall at elias.schisgall@wsj.com

(END) Dow Jones Newswires

May 08, 2026 17:41 ET (21:41 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/2634846033"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2634846033\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2634846033?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-09 05:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2634846033","market":"sh","top_or_hot":-1,"title":"Inhibrx Biosciences' Shares Up Ahead of Phase 2 Head and Neck Cancer Drug Data","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Elias Schisgall \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/INBX\">Inhibrx Biosciences</a> rose after the clinical-stage biopharmaceutical company said it would release data from a Phase 2 study of INBRX-106, a potential cancer treatment. \n</p>\n<p>\n  Shares were up 6.4% to $142.90 after the bell on Friday. The stock closed up 7.9% at $134.35, and has risen more than 1,000% in the past 52 weeks. \n</p>\n<p>\n  The company will read out the data in a webcast at 8:30 a.m. ET on Monday. \n</p>\n<p>\n  INBRX-106, a hexavalent OX40 agonist, is being tested in combination with pembrolizumab to treat metastatic or unresectable recurrent Head and Neck Squamous Cell Carcinoma. It is being tested against pembrolizumab as a monotherapy. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 08, 2026 17:41 ET (21:41 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Inhibrx Biosciences' Shares Up Ahead of Phase 2 Head and Neck Cancer Drug Data</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInhibrx Biosciences' Shares Up Ahead of Phase 2 Head and Neck Cancer Drug Data\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-05-09 05:41</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Elias Schisgall \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/INBX\">Inhibrx Biosciences</a> rose after the clinical-stage biopharmaceutical company said it would release data from a Phase 2 study of INBRX-106, a potential cancer treatment. \n</p>\n<p>\n  Shares were up 6.4% to $142.90 after the bell on Friday. The stock closed up 7.9% at $134.35, and has risen more than 1,000% in the past 52 weeks. \n</p>\n<p>\n  The company will read out the data in a webcast at 8:30 a.m. ET on Monday. \n</p>\n<p>\n  INBRX-106, a hexavalent OX40 agonist, is being tested in combination with pembrolizumab to treat metastatic or unresectable recurrent Head and Neck Squamous Cell Carcinoma. It is being tested against pembrolizumab as a monotherapy. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 08, 2026 17:41 ET (21:41 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2634846033","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2634846033","pubTimestamp":1778276460,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Inhibrx Biosciences rose after the clinical-stage biopharmaceutical company said it would release data from a Phase 2 study of INBRX-106, a potential cancer treatment.Shares were up 6.4% to $142.90 after the bell on Friday. The stock closed up 7.9% at $134.35, and has risen more than 1,000% in the past 52 weeks.The company will read out the data in a webcast at 8:30 a.m. ET on Monday.INBRX-106, a hexavalent OX40 agonist, is being tested in combination with pembrolizumab to treat metastatic or unresectable recurrent Head and Neck Squamous Cell Carcinoma. It is being tested against pembrolizumab as a monotherapy.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","INBX":"Inhibrx Biosciences"},"translate_title":"Inhibrx Biosciences股价在2期头颈癌药物数据公布前上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INBX":1.5},"content_text":"By Elias Schisgall \n\n\n \n\n\n  Shares of Inhibrx Biosciences rose after the clinical-stage biopharmaceutical company said it would release data from a Phase 2 study of INBRX-106, a potential cancer treatment. \n\n\n  Shares were up 6.4% to $142.90 after the bell on Friday. The stock closed up 7.9% at $134.35, and has risen more than 1,000% in the past 52 weeks. \n\n\n  The company will read out the data in a webcast at 8:30 a.m. ET on Monday. \n\n\n  INBRX-106, a hexavalent OX40 agonist, is being tested in combination with pembrolizumab to treat metastatic or unresectable recurrent Head and Neck Squamous Cell Carcinoma. It is being tested against pembrolizumab as a monotherapy. \n\n\n \n\n\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 08, 2026 17:41 ET (21:41 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}